US 12,228,581 B2
Adrenomedullin assays and methods for determining mature andrendomedullin
Andreas Bergmann, Berlin (DE)
Assigned to SPHINGOTEC GMBH, Hennigsdorf (DE)
Filed by SPHINGOTEC GMBH, Hennigsdorf (DE)
Filed on Jun. 23, 2023, as Appl. No. 18/340,235.
Application 15/344,784 is a division of application No. 14/358,147, granted, now 9,535,060, issued on Jan. 3, 2017, previously published as PCT/EP2012/072928, filed on Nov. 16, 2012.
Application 18/340,235 is a continuation of application No. 17/349,134, filed on Jun. 16, 2021, granted, now 11,726,101.
Application 17/349,134 is a continuation of application No. 15/344,784, filed on Nov. 7, 2016, granted, now 11,067,586, issued on Jul. 20, 2021.
Claims priority of application No. 11189447.3 (EP), filed on Nov. 16, 2011; application No. 11189448.1 (EP), filed on Nov. 16, 2011; application No. 11189449.9 (EP), filed on Nov. 16, 2011; application No. 11189450.7 (EP), filed on Nov. 16, 2011; application No. 11189452.3 (EP), filed on Nov. 16, 2011; application No. 12160014.2 (EP), filed on Mar. 16, 2012; application No. 12160015.9 (EP), filed on Mar. 16, 2012; application No. 12160016.7 (EP), filed on Mar. 16, 2012; application No. 12160017.5 (EP), filed on Mar. 16, 2012; application No. 12160018.3 (EP), filed on Mar. 16, 2012; and application No. 12186449.0 (EP), filed on Sep. 27, 2012.
Prior Publication US 2024/0085438 A1, Mar. 14, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/53 (2006.01); G01N 33/74 (2006.01)
CPC G01N 33/74 (2013.01) [G01N 2800/26 (2013.01); G01N 2800/52 (2013.01)] 22 Claims
 
1. A method for therapy comprising:
forming a complex in a plasma or whole blood sample from a human patient suspected of having sepsis, said complex comprising mature adrenomedullin (ADM) 1-52 and/or mature ADM 1-52-Gly in said sample of plasma or whole blood of said human patient suspected of having sepsis and two antibodies that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is SEQ ID No. 1 or SEQ ID No. 2 wherein each of said regions comprises at least 4 or 5 amino acids, and
measuring the amount of complex formed and
treating the human patient suspected of having sepsis, and
wherein the treatment is not provided as a follow-up treatment.